Cost-effectiveness of a pediatric dengue vaccine
Shepard, D.S.; Suaya, J.A.; Halstead, S.B.; Nathan, M.B.; Gubler, D.J.; Mahoney, R.T.; Wang, D.N.C.; Meltzer, M.I.
Vaccine 22(9-10): 1275-1280
2004
ISSN/ISBN: 0264-410X PMID: 15003657 DOI: 10.1016/j.vaccine.2003.09.019Document Number: 275923
To ascertain the economic feasibility of a pediatric tetravalent dengue vaccine, we developed and calibrated a cost-effectiveness model of vaccinating children at 15 months in Southeast (SE) Asia using a societal perspective. We assumed that full immunization would require two doses at prices of US$ 0.50 and US$ 10 per dose in the public and private sectors, respectively. The gross cost per 1000 population (of all ages) of the vaccination program would be US$ 154. Due to projected savings in dengue treatment, the net cost per capita would be only US$ 17 (89% below the gross cost). The cost per disability adjusted life year (DALY) saved by a pediatric vaccine would be US$ 50, making the potential vaccine highly cost-effective. Eventually, vaccination may be able to replace environmental control as a strategy for dengue prevention and be cost saving.
Document emailed within 0-6 h
